Since GPX1 plays a fundamental role in metabolizing intracellular ROS and maintaining hemostasis of cells, it is reasonable to hypothesize that elimination of ROS induced by cisplatin treatment may be the associated mechanism for GPX1 induced resistance to cisplatin in lung cancer. The gene discussed is GPX1; the disease is lung carcinoma.